Read, Watch or Listen

A German study suggests that a daily nasal spray containing azelastine, a common allergy medication, may significantly reduce COVID-19 infection rates. In a trial involving 450 adults, those using the spray experienced a 67% lower infection rate compared to a placebo group. While the sample size was relatively small, the results also indicated a slower infection onset and shorter positive test duration in the azelastine group. The spray also seemed to reduce other respiratory infections. Larger studies are needed to confirm these promising findings.

Prepared by Olivia Bennett and reviewed by editorial team.